Research and Markets: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xh9c6g/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018" report to their offering.
“OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018”
Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options for acne, though with the exception of isotretinoin, most only provide symptomatic relief as opposed to a curative or disease-modifying solution. However, isotretinoin is unable to serve a significant proportion of the acne market owed to its teratogenic nature, making its prescription for women of child-bearing age problematic.
In the past decade, there has been a shift in the acne market, with greater appreciation of its patient pool and potential for a lucrative payoff. Furthermore, there has been greater stress put on the social and psychological implications of the disease, which impact patients' quality of life. As a result, R&D investments have been initiated by key pharmaceutical players.
Key strategies underway in the acne market include:
- Drive for combination therapies, for example, Galderma's Epiduo (adapalene and benzoyl peroxide), which continues to experience rapid uptake.
- Expansion of the market into the pediatric population and for late-onset acne in women.
- A push towards disease-modifying therapies; for example, launch of AndroScience's ASC-J9 androgen receptor degradation enhancer is anticipated to be a game-changer and is expected to rival isotretinoin, the current market leader for severe acne.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Current Treatment Options
6 Unmet Needs Assessment and Opportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/xh9c6g/opportunityanalyze